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Abstract 
Mycoplasmas are amongst the most successful pathogens of both humans and animals yet the molecular basis of 
mycoplasma pathogenesis is poorly understood. This is partly due to the lack of classical virulence factors and little sim‑
ilarity to common bacterial pathogenic determinants. Using Mycoplasma agalactiae as a model we initiated research 
in this direction by screening a transposon mutant library in the natural sheep host using a negative selection method. 
Having successfully identified putative factors involved in the colonization of local infection and lymphogenic sites, the 
current study assessed mutants unable to spread systemically in sheep after experimental intramammary infection. 
Analysis of distant body sites for complete absence of mutants via SSM PCR revealed that additional set of genes, such 
as pdhB, oppC, oppB, gtsB, MAG1890, MAG5520 and MAG3650 are required for systemic spreading apart from those that 
were necessary for initial colonization. Additional in vitro studies with the mutants absent at these systemic sites con‑
firmed the potential role of some of the respective gene products concerning their interaction with host cells. Mutants 
of pdhB, oppC and MAG4460 exhibited significantly slower growth in the presence of HeLa cells in MEM medium. This 
first attempt to identify genes exclusively required for systemic spreading provides a basis for further in‑depth research 
to understand the exact mechanism of chronicity and persistence of M. agalactiae.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Mycoplasma agalactiae is mainly responsible for the con-
tagious agalactia (CA) syndrome in small ruminants. As 
an economically important disease, CA is enlisted as a 
notifiable disease by the World Organization for Animal 
Health. Shedding of the pathogen by diseased or asymp-
tomatic carriers continues for months or years after the 
initial infection, with a potential risk of transmitting 
the agent to other susceptible animals [1–3]. Antibiotic 
therapy tends to reduce the clinical signs, but promotes 
the carrier state [4]. Hence, chronicity and persistence 
are hallmarks of M. agalactiae infections that make it 
difficult to eradicate. Due to its well-known clinical signs 
and the capacity to establish experimental infections, M. 
agalactiae serves as a useful model to study mycoplasma 
pathogenesis in its natural host.
Genome sequencing of the M. agalactiae PG2 type 
strain revealed that several of its genetic loci have been 
horizontally transferred from the mycoides cluster [5]. 
However, its virulence mechanisms and factors involved 
in pathogenesis and disease progression are yet to be 
understood at the molecular level. Our effort to deci-
pher the pathogenesis of M. agalactiae was initiated by 
gene disruption through homologous recombination and 
transposon mutagenesis [6, 7]. These studies have dem-
onstrated the role of the vpma locus in M. agalactiae 
pathogenesis [8]. Also, recently we attempted to identify 
potential pathogenicity factors of M. agalactiae in the 
natural sheep host by negative selection of transposon 
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mutants [9]. Other independent studies using transposon 
mutants were able to show the role of different genomic 
loci in interaction with host cells [10] and the results 
obtained were further evaluated in vivo to conclude that 
the NIF locus was important for the pathogenicity of M. 
agalactiae [11]. Recently, we have shown that M. aga-
lactiae can invade eukaryotic cells in  vivo and in  vitro 
and also demonstrated its ability to disseminate sys-
temically throughout the body of the infected host after 
experimental intramammary infection [12]. However, a 
comprehensive analysis of the molecular genetic factors 
involved in the systemic spread of M. agalactiae in its 
natural host has not been performed.
Systemic spread of M. agalactiae after intramammary 
infection is well established [12]. In a recent experimen-
tal infection trial using pools of transposon mutants for 
intramammary infection of lactating ewes, we identi-
fied transposon mutants absent at the local site of infec-
tion and lymph nodes (LNs) [9]. The present study is 
an extension of the latter work, where we have further 
assessed the presence or absence of specific mutants 
in several inner organs distant from the site of inocu-
lation. These data reveal the importance of additional 
genes required for systemic spread inside the host. The 
identified mutants belonging to different functional 
categories were analyzed in  vitro using cell cultures to 
establish their role in interactions with host cells.
Materials and methods
Mycoplasma cultures and growth conditions
The M. agalactiae type strain PG2 [5, 13] and all myco-
plasma cultures were grown as described previously [9]. 
Gentamicin sulphate (50 µg/mL) was added when propa-
gating transposon mutants.
Transposon mutants and identification of insertion sites
Transposon Tn4001mod [14] was used to construct M. 
agalactiae insertional mutants, as described previously 
[7]. Transposon insertion sites were identified using a 
recently described novel sequencing method [9] based 
on ligation-mediated QTD PCR [15]. The position 
of the transposon in the genome was determined by 
nucleotide BLAST in Molligen 3.0 [16].
Growth analysis and stability of transposon mutants
Growth rate and insertion stability of each of the trans-
poson mutants was assessed in Aluotto medium as 
described previously [9].
Signature sequence mutagenesis (SSM) PCR
SSM PCR is based on genetic footprinting for the identifi-
cation of attenuated mutants in vivo [17] and was modified 
and performed on M. agalactiae as described previously [9].
Animals and ethical statement
Screening was performed in 1.5 to 2  year-old lactating 
ewes of a local breed attested to be free of mycoplasmas 
and other pathogenic bacteria. Experiments were con-
ducted according to the guidelines of the Ethics Commit-
tee of the University of Veterinary Medicine Vienna and 
the Austrian Federal Ministry for Science and Research 
(approval numbers BMWF-68.205/002-II/3b/2011 and 
BMWF-68.205/0104-II/3b/2012).
Initial and secondary screening of transposon mutants
A total of 9 sheep were used in the initial round of 
screening to test 45 different transposon mutants as 
described previously [9] except that some additional 
distant organs, including the spleen, liver, lungs, uterus, 
kidneys and synovial fluids from stifle joints were also 
analyzed. Five mutants were kept common between the 
groups as “watermarks”, and are underlined in Table 1.
Based on the SSM PCR results and a cut-off for absence 
of ≥95%, a total of 14 mutants were found to be absent in 
udders, LNs and systemic sites during initial screening. 
These mutants were re-screened in a second round of con-
firmatory screening in three sheep that were also infected 
via the intramammary route using the same procedures as 
described previously [9]. Apart from all the tissue samples 
tested during the initial screening experiment, the brain, 
heart, and carpal joint tissues were also examined. Fur-
thermore, the presence or absence of M. agalactiae in all 
the tissue samples from the mutant-infected animals was 
compared with the systemic spread of wild type M. agalac-
tiae strain PG2, which was experimentally inoculated into 
two sheep in parallel as a positive control group [12].
Cell culture
HeLa-229 (ATCC CCL-2.1) and J774A.1 (ATCC TIB-
67) cell lines certified to be free of mycoplasmas were 
purchased from the American Type Culture Collection 
(ATCC; Manassas, USA). HeLa-229 cells were main-
tained in minimum essential medium (MEM) with 10% 
heat-inactivated foetal bovine serum (FBS) and J774A.1 
cells were propagated in DMEM with 10% FBS and 
2  mM  l-glutamine (Sigma). Trypsin and 1×  PBS were 
purchased from PAA Laboratories GmbH (Pasching, 
Austria) or Sigma-Aldrich. All cell cultures were regu-
larly checked for mycoplasma contamination by culture 
and PCR techniques.
Quantitative growth analysis in presence of mammalian 
cells
The ability of the mutants and the wild type PG2 strain 
to grow in the presence of HeLa cells was examined 
quantitatively by individual co-cultivation experiments. 
The mutants and wild type strain PG2 were grown as 
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described before. PG2 and mutant cultures were diluted 
in MEM and inoculated onto 4  ×  104 HeLa cells/well 
(MOI of 10–50) in 24-well tissue culture plates (CELL-
STAR® Greiner Bio-One GmbH, Germany). The infected 
cells were incubated at 37 °C with 5% CO2 for 48 h. HeLa 
cells were trypsinized and cell suspensions were serially 
diluted in SP4 medium before plating on SP4 agar plates 
containing appropriate antibiotics. Control wells with-
out HeLa cells did not yield any PG2 or mutant strains’ 
growth in MEM. All the experiments were carried out 
at least three times as duplicates. The results are repre-
sented as doubling times calculated using the following 
formula:
Doubling time = (t2 − t1) × (log (2)/log (cfu at t2/cfu at t1)
t1 = Starting time of assay; t2 = End time of assay
Macrophage cytotoxicity assay
The ability of M. agalactiae to kill infected J774.A1 
murine macrophages was assessed quantitatively using a 
colorimetric assay. The release of lactate dehydrogenase 
(LDH) was quantified using the CytoTox 96® Non-Radi-
oactive cytotoxicity assay kit (Promega). Initially, pilot 
experiments with uninfected J774A.1 cells were per-
formed to determine the optimum number of target cells 
to be used with the CytoTox 96® assay according to the 
manufacturer’s instructions. A 96-well V-bottom micro-
titre plate containing 5 × 103 J774.A1 cells/well was inoc-
ulated separately with M. agalactiae wild type strain PG2 
and each of the 14 different transposon mutants to get 
an MOI of about 100. Uninfected J774.A1 cell controls 
were observed to be intact. The plates were centrifuged 
Table 1 List of mutants screened in the initial round of screening in an intramammary sheep infection model
Mutants kept common (“watermarks”) between the groups are underlined and those shortlisted for secondary screening showing >95% absence are in italics.
Group I-15 mutants Group II-17 mutants Group III-19 mutants
Mutant Genes disrupted Mutant Genes disrupted Mutant Genes disrupted
Apo7 Hypothetical Protein (MAG1890) Apo2-12 Hypothetical protein, predicted lipopro-
tein (MAG1050)
3‑20 NADH oxidase (nox)
Apo6 Sugar isomerase (araD) 1‑3‑0 Hypothetical protein (MAG2810) 13 VpmaX
26 Oligopeptide transporter ATP binding 
protein (oppF)
15‑2 Hypothetical protein, predicted lipo‑
protein (MAG6200)
14 DNA methylase (MAG1790)
3‑15 Elongation factor G (fusA) 170 Hypothetical protein (MAG0110) 137 Hypothetical protein (MAG4460)
6-9-2 Oligopeptide ABC transporter permease 
(oppC)
3-29 Hypothetical protein/Vpma like pre-
dicted lipoprotein (MAG2540)
8‑1 Deoxyguaosine kinase (dgk)




6‑21 Cell division protein (mraZ) 8 + 1‑4 ABC transporter ATP‑binding protein 
(MAG5960)
96‑2 ATP synthase (atpA)
6-29 Pyruvate dehydrogenase beta subunit 
(pdhB)
8 + 1‑8 Transport protein SGAT (ulaA) 5‑1 Hypothetical protein (MAG0250)
6-32 Phosphate acetyl transferase (eutD) 3-4-0 Hypothetical protein (MAG3390) 6‑13 Hypothetical protein (MAG1570)
7 + 1‑8 Hypothetical protein (MAG4010) 9‑28 Conserved hypothetical protein 
(MAG0390)
7 + 1-3 Conserved hypothetical protein 
(MAG3650)
9-40 Glycerol ABC transporter permease 
component (gtsB)







8 + 1‑5 Ribonuclease H II (rnhB) 8 + 1‑5 Ribonuclease H II (rnhB)
9-31 Alcohol dehydrogenase (adhT) and 
NADH oxidase (nox)
9-31 Alcohol dehydrogenase (adhT) and 
NADH oxidase (nox)
6‑15 Esterase/lipase (lip) 6‑15 Esterase/lipase (lip)
81-1 Oligopeptide ABC transporter per-
mease (oppB)
81-1 Oligopeptide ABC transporter permease 
(oppB)
9‑8 Dihydrolipoamide dehydrogenase 
(pdhD)
6‑12 Transcriptional regulator (MAG6310)
212 Type III restriction modification sys‑
tem (MAG1530)
San5 Predicted lipoprotein (MAG3120)
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at 250 × g for 4 min at room temperature and incubated 
at 37 °C with 5% CO2 for 24 h. The released LDH, an indi-
cator of macrophage cell lysis, was calculated using the 
formula provided with the kit protocol and expressed as 
a percentage of cytotoxicity. The assay was performed in 
triplicate at least twice.
Statistical analysis
The SSM PCR results for each mutant were expressed as 
average percentage absence  ±  standard deviation from 
each group of three sheep. Cut-off criteria of ≥95% and 
100% absence was used for considering the mutants 
absent during the initial and secondary rounds of screen-
ing, respectively, and were compared using the Mann–
Whitney test [18]. The results of the in vitro assays were 
compared using the unpaired parametric Student’s t test 
using GraphPad Prism 5 (Graphpad Software Inc, CA, 
USA), and a value of p < 0.05 was considered significant.
Results
Identification of M. agalactiae genes required for systemic 
spread
A total of 45 mutants, which exhibited stable transpo-
son insertions and normal growth profiles except pdhB 
mutant [9, 19], were tested in the initial round of screen-
ing by intramammary infection of lactating ewes in three 
different groups, as described in Table  1. Two weeks 
post-infection (pi), samples of the right and left kidneys, 
lungs, uterus, liver, spleen and synovial fluids from stifle 
joints were checked for the presence of M. agalactiae by 
culture and PCR [20], and if positive then for the pres-
ence or absence of specific mutants via SSM PCR. Liver, 
spleen and left lungs were found to be negative for the 
presence of M. agalactiae in all the nine sheep, whereas 
the uterus, right lungs, kidneys and synovial fluids from 
stifle joints were positive in some sheep. An additional 
table summarizes the frequency of isolation of M. agalac-
tiae from various systemic sites tested in this study (see 
Additional file 1).
SSM PCR analysis of M. agalactiae positive samples 
revealed the presence or absence of specific mutants in 
each of the three sheep of each infected group. Several 
mutants with disruptions in genes including rnhII, ptsL, 
fusA, araD and lplA were found at systemic sites includ-
ing the uterus and synovial fluids of the stifle joints, 
thereby demonstrating that these gene defects do not 
affect their ability to colonize these inner organs. How-
ever, a total of 14 mutants, including the “watermark” 
mutants 9-31 and 81-1, had an average absence percent-
age of ≥95% (Table 1) in all the tested samples.
As it was difficult to perform individual challenge 
experiments in sheep with all the 14 attenuated mutants 
for reasons described previously [9], a second round of 
confirmatory screening was carried out, as is usually 
done during negative selection studies [21, 22]. Having 
confirmed the stability of the transposon, the 14 attenu-
ated mutants were also shown to have no competitive 
growth deficits when subjected to an in vitro mixed cul-
ture growth assay [9]. Analyses of tissue samples from 
heart, brain and carpal joint (left and right) in addition 
to lungs, kidneys, spleen, liver, uterus and synovial fluids 
of the stifle joints were performed to detect the presence 
of mycoplasmas in systemic sites. M. agalactiae wild type 
strain PG2-infected sheep served as parallel positive con-
trols [12]. Compared to the latter group, in which several 
systemic sites were positive for M. agalactiae (Additional 
file 1), none of the three sheep infected with the 14 trans-
poson mutants had detectable M. agalactiae in any of the 
13 systemic sites tested per sheep by PCR and culture, 
using both direct plating and enrichment studies. Seven 
of these mutants were exclusively absent only at the sys-
temic sites and were present in the infected udders and 
surrounding lymph nodes (Table 2). The 100% absence of 
these 14 mutants in all three sheep of the confirmatory 
screening clearly demonstrates their inability to dissemi-
nate into distant body sites. The wild type PG2 strain, on 
the other hand, was able to cause systemic infection, as 
confirmed by PCR (Additional file  1) and immunohis-
tochemical analysis [12]. Hence, these results indicate 
that the transposon insertions into specific genes were 
responsible for the inability of these mutants to spread 
systemically and colonize distant body sites.
In order to estimate the reproducibility of results 
obtained with common “watermark” mutants between 
different groups, the Mann–Whitney test [18] was 
applied. No significant difference was detected in average 
percentage of absence (p  >  0.05) of attenuated mutants 
that are common between the groups.
Phenotypic analysis of attenuated mutants
As the in vivo screening identified a relatively high num-
ber of genes required for systemic spread, and especially 
Table 2 Mutants showing complete absence exclusively 
at the systemic sites of all three infected sheep





6-29 MAG0940_pdhB 19, 40‑44
9-40 MAG2320_gtsB 28, 36‑37
7 + 1-3 MAG3650
23 MAG5520_aminopeptidase 44
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because we could not test each of the 14 mutants in indi-
vidual infection trials to compare with wild type PG2 
strain, we decided to assess their in  vitro interactions 
with host cells in cell culture. The ability of the mutants 
to grow in the presence of mammalian cells like HeLa and 
their involvement in the killing of murine macrophages 
have been previously reported to be important character-
istics for evaluating their potential role in pathogenicity 
and systemic spread [10, 11, 23, 24]. Moreover, as we had 
earlier reported the presence of M. agalactiae wild type 
strain PG2 in lung macrophages of infected sheep [12], 
we wanted to check if there was any defect in the ability 
of the mutants to infect non-phagocytic cells and if they 
caused any cytotoxicity in macrophages.
HeLa cells were co-cultivated with the wild type strain 
PG2 and also separately with each of the 14 mutants that 
could not spread systemically and were not isolated from 
any of the distant inner organs of infected sheep. The 
in  vitro results showed that pdhB, oppC and MAG4460 
mutants exhibited significantly slower growth in the 
presence of HeLa cells as compared to the PG2 strain 
(Figure 1).
The ability of the mutants to kill murine macrophages 
was assessed in comparison to the wild type strain using 
a non-radioactive assay. Although none of the mutants 
had significant alterations in their killing capacity com-
pared to the wild type PG2 strain, the mutant MAG5520 
was nearly two-fold deficient (p  >  0.05) in its cytotoxic 
effect on macrophages (Figure  2). This mutant showed 
only 13% macrophage killing at 24 h pi, whereas the wild 
type strain exhibited a cytotoxic rate of about 27%. All 
the other 14 mutants demonstrated a cytotoxic potential 
comparable to that of the wild type strain (Figure 2).
Discussion
Bacteria belonging to the genus Mycoplasma are capable 
of causing chronic and persistent infections in a variety 
of hosts. As a pathogen of small ruminants, M. agalac-
tiae is capable of subverting the host immune response 
likely through its sophisticated Vpma antigenic variation 
system [8], and by intracellular residence and spread to 
distant safer host niches [12]. Until our recent study [9], 
which identified mutants unable to colonize the initial 
local infection site and associated LNs during experi-
mental intramammary infection, the molecular basis of 
M. agalactiae pathogenesis had been little studied. The 
aim of the study presented here was to identify in the 
sheep intramammary infection model genetic factors 
of M. agalactiae that play a role in its systemic spread-
ing to distant sites in the natural host. Our previous 
analysis of the local infection site revealed the absence 
of 7 mutants belonging to different functional catego-
ries [9]. Further analysis of distant inner organs and host 
sites has now revealed 7 additional transposon mutants 
that exclusively show 100% absence in all three sheep at 
these sites (Table 2). The genomic loci corresponding to 
these mutants seem to play an exclusive and important 
role in the systemic spreading of M. agalactiae from the 
site of initial infection (Figure 3). Unlike the other seven 
mutants that were unable to colonize the local infection 
site (udder) and LNs [9], the additional set of 7 mutants 
Figure 1 Growth analysis of selected transposon mutants 
during co-cultivation with HeLa cells. Doubling time, in pres‑
ence of HeLa cells 48 h pi, of the wild type strain PG2 and trans‑
poson mutants deficient in systemic spreading is shown. Each bar 
represents the average doubling time ± standard deviation of three 
independent experiments done in duplicates. *p < 0.05; **p < 0.005.
Figure 2 Macrophage cytotoxicity assay of selected transpo-
son mutants in murine macrophages. Percentage cytotoxicity 
of the wild type strain PG2 and selected transposon mutants in 
J774.A1 cells at 48 h pi is depicted. Each bar represents the average 
percentage cytotoxicity ± standard deviation of three independent 
experiments done in triplicates.
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were absent only at systemic sites (Table 2). These results 
suggest that having established a successful infection 
at the local sites, such as udders, this ruminant patho-
gen employs additional factors to spread systemically to 
newer distant host niches. Hence, the mutants absent at 
the distant inner organs not only correspond to genes 
required for initial infection but also those that play 
important roles in the systemic spreading of the patho-
gen (Figure  3). Among the mutants absent exclusively 
at the distant systemic sites, some of the corresponding 
genes, such as oppB, oppC and gtsB, are reported to be 
acquired from mycoides cluster through horizontal gene 
transfer [5], perhaps under selection pressure to possibly 
provide additional advantages of systemic spreading and 
thus persistence. Hence, genetic factors identified for M. 
agalactiae pathogenicity could also be important in the 
infection biology of the mycoplasma species belonging to 
the mycoides cluster.
Metabolic proteins and transporters are known to play 
a crucial role in mycoplasma pathogenesis [25–28]. Our 
study identified two genes coding for the permease com-
ponent of an oligopeptide transporter, namely oppB and 
oppC. Although Mycoplasma hominis OppA has been 
implicated in mammalian cell adhesion and apoptotic 
cell death [29, 30], involvement of permease components 
in virulence has been so far reported only in pathogenic 
bacteria other than mycoplasmas [31–34]. In addition, 
the mutant oppC is also growth-deficient in the pres-
ence of HeLa cells, indicating that the transport of pep-
tides is important for both in  vitro and in  vivo survival 
of M. agalactiae in presence of host cells. Based on these 
in vitro and in vivo data, nutrient acquisition such as the 
uptake of small peptides seems to play an important role 
in the survival of M. agalactiae in the host. Addition-
ally, like several other mycoplasma species, M. agalactiae 
has retained both the parent Opp operon as well as the 
horizontally transferred locus [35], further indicating its 
significant role in pathogenesis. Likewise, glycerol seems 
to play a crucial role in mycoplasma pathogenesis as a 
substrate for toxic metabolic products like H2O2 [28, 36]. 
In this study, a mutant defective in the permease com-
ponent of a glycerol ABC transporter (gtsB) was unable 
to spread to or survive in the systemic sites. The genes 
involved in transport and metabolism of glycerol have 
been previously reported as important virulence factors 
[25–27, 36]. The glycerol transport locus is well charac-
terised in members of the mycoides cluster [37] and has 
been shown to play a role in virulence [28]. As M. agalac-
tiae has probably acquired its gtsABC from the mycoides 
cluster through horizontal gene transfer [35], it is likely 
that this locus also plays a role in its pathogenesis. How-
ever, unlike the members of the mycoides cluster, M. aga-
lactiae lacks the gene for the active transport of glycerol, 
as well as that encoding for glycerol phosphate oxidase, 
Figure 3 Genomic loci that play a potential role in the systemic spread of M. agalactiae. Transposon mutants completely absent in LNs 
and udders are depicted in red (LU) whereas those that were present at latter sites but exclusively absent only at systemic sites are shown in green 
(S). The black arrows represent the location of transposon insertion sites in the respective genes.
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both of which are primarily responsible for H2O2 produc-
tion. Taking into account that the gtsB mutant was found 
to be attenuated in this study, further analyses could lead 
to interesting findings.
Apart from oligopeptide transporter genes, a mutant 
with a disrupted pdhB gene, coding for the beta subu-
nit of the pyruvate dehydrogenase complex, was also 
absent in the systemic sites. This gene is responsible for 
the metabolism of pyruvate, which is the major energy 
yielding process in M. agalactiae [38]. The pdhB mutant 
showed reduced growth in axenic medium during loga-
rithmic phase, but was recovered in vivo from the udder 
and LNs of infected animals in the confirmatory screen-
ing experiment [9, 19], indicating its relative survival in 
local sites of infection. Additionally, this mutant also 
showed reduced invasion into HeLa cells [19], indicat-
ing its role in host cell invasion and the significance of 
the latter in the systemic spread of M. agalactiae. In 
other words, the absence of this mutant at distant sys-
temic sites shows its inability to disseminate through-
out the body to cause systemic infection, which in turn 
could be due to its reduced invasiveness. As systemic 
spread and cell invasion are often related [12, 39], it is 
possible that the mutant’s inability to cross the epithelial 
barrier might be responsible for its deficient spreading 
capacity. Additionally, the pdhB mutant also showed a 
growth defect in the presence of HeLa cells in vitro and 
this might be due to its inability to interact with host 
cell proteins. Earlier studies with Mycoplasma pneumo-
niae have shown that PdhB is surface localised [40] and 
binds fibronectin and plasminogen [41, 42]. Thus, like 
many other mycoplasmas [43, 44], M. agalactiae might 
also be utilising a single gene product to carry out mul-
tiple functions.
Aminopeptidases play important roles in pathogenesis 
of bacteria by providing a source of amino acids from 
exogenous proteins by destroying host immunological 
effector peptides. A M. agalactiae mutant containing 
transposon insertion in the gene coding for glutamyl ami-
nopeptidase (MAG5520) was unable to spread inside the 
infected sheep. This mutant also showed reduced killing 
of murine macrophages as measured in the cytotoxicity 
assay. A similar protein in Mycoplasma hyopneumoniae 
was shown to be surface-located, involved in adhesion 
and capable of binding and cleaving plasminogen [44]. 
Interestingly, the latter exhibits more than 50% identity 
to the M. agalactiae aminopeptidase and might have the 
same characteristics. Hence, it is possible that disruption 
of this gene results in reduced ability to generate amino 
acids for M. agalactiae’s survival inside the host.
In addition to mutants in annotated genes, this study 
also identified loci coding for hypothetical or conserved 
hypothetical proteins. Mutants with disruptions in 
MAG1890 and MAG3650 genes encoding proteins of 
unknown functions were found attenuated only in sys-
temic sites but were recovered from the udders and LNs. 
An independent study had earlier shown that transpo-
son insertion in MAG1890 resulted in reduced interac-
tion of M. agalactiae with goat embryo fibroblast cells 
[45]. However, our studies with HeLa cells did not show 
a significant difference in co-culture growth (p  >  0.05) 
and this may be due to the differences in the cell lines 
used. Sequence analysis of MAG3650 showed 86% iden-
tity to a putative membrane protein of Mycoplasma bovis 
(MBOVPG45_0454). Since these ruminant mycoplasmas 
are phylogenetically closely related and even cause simi-
lar infections in their respective hosts, they also might 
share their protein functions. Thus, MAG3650’s corre-
sponding homolog MBOVPG45_0454 might also play 
a critical role in the pathogenicity of the economically 
more important M. bovis. These results indicate that, 
apart from known lipoproteins, transporters and meta-
bolic proteins acting as virulence factors, hypothetical 
proteins might also play a crucial role in M. agalactiae 
pathogenesis.
Altogether, the study presented here has shown the 
possible role of several genomic loci (Figure 3) involved 
in systemic spreading of M. agalactiae during experi-
mental intramammary infection of lactating ewes. The 
results provide a better understanding of how M. agalac-
tiae utilizes its genomic machinery to establish systemic 
infection in its natural host. To our knowledge, this is the 
first report describing the potential role of a set of genetic 
factors involved in systemic infections of a ruminant 
mycoplasma. Further studies of these factors in individ-
ual infection experiments could pave the way in identify-
ing a suitable mutant that could be developed further as a 
good vaccine candidate.
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